In Treatment of Iron overload Iron overload, as the name suggests, means excess of iron in the human body. Too much iron can cause organ damage, which can lead to conditions such as cancer, irregular heartbeat and cirrhosis of the liver. Symptoms are related to conditions that arise from iron overload such as high blood sugar levels (diabetes), darkening of the skin, abnormal heart rhythm or arthritis. By using Deferataj 250mg Tablet DT, this excess of iron can be decreased to safe levels by removing it from the body through stools. This helps to reduce the risk of organ damage and prevents further complications. Take Deferataj 250mg Tablet DT as prescribed by the doctor to get the maximum benefit.
It is not known whether it is safe to consume alcohol with Deferataj 250mg Tablet DT. Please consult your doctor.
Deferataj 250mg Tablet DT may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Deferataj 250mg Tablet DT is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Deferataj 250mg Tablet DT may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Deferataj 250mg Tablet DT is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor.
Deferataj 250mg Tablet DT should be used with caution in patients with liver disease. Dose adjustment of Deferataj 250mg Tablet DT may be needed. Please consult your doctor. Limited information is available on the use of Deferataj 250mg Tablet DT in these patients.
If you miss a dose of Deferataj 250mg Tablet DT, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Cipla Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Sun Pharmaceutical Industries Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Globela Pharma Pvt Ltd || ₹14.5/tablet (25% cheaper)